Results you can have confidence in. ADXBLADDER delivers a simple, rapid and highly reliable diagnosis of bladder cancer from urine.

There are 150,000 bladder cancer
diagnoses in EU per year

Ferlay J et al. Cancer incidence and mortality patterns in
Europe: Estimates for 40 countries in 2012.
Eur J Cancer 49(6), 1374-1403 (2013).

Bladder cancer has a 65%
recurrence rate, the highest of
any malignancy

National Cancer Institute’s SEER database

The gold-standard diagnostic test
for bladder cancer, cystoscopy, is
invasive, uncomfortable
and expensive

5 million haematuria patients
undergo cystoscopy in Europe
each year

Ferlay J et al. Cancer incidence and mortality patterns in
Europe: Estimates for 40 countries in 2012.
Eur J Cancer 49(6), 1374-1403 (2013)

Only 10% of haematuria patients are
typically diagnosed with
bladder cancer

Edwards TJ, Dickinson AJ, Natale S, et al. A prospective analysis
of the diagnostic yield resulting from the attendance of 4020
patients at a protocol-driven haematuria clinic.
BJU Intl 2006; 97(2): 301–5

White Light Cystoscopy is
considered the gold standard
test for bladder cancer

Deshpande A et al. Bladder cancer diagnosis and management. GM, 06, 2014.

Up to 30% of bladder cancers are
missed at initial cystoscopy

Jocham D et al. Photodynamic diagnosis in urology: state-of-the-art.
Eur Urol 53(6): 1138-48 (2008) Zhangqun Ye et al.
A comparison of NBI and WLI cystoscopy in detecting
non-muscle-invasive bladder cancer:
A prospective, randomized and multi-center study. Sci Rep.; 5:10905 (2015).

 

Results you can have confidence in

ADXBLADDER delivers a simple, rapid and highly reliable diagnosis
of bladder cancer from urine.

SIMPLE

  • Simplifies the diagnostic process
  • Is an easy-to-use ELISA test
  • Can be performed on a full void of urine as small as 10 mL

RAPID

  • Uses well-established ELISA technology to deliver a rapid result. The test can be run in as little as 2.5 hours
  • Sample collection is quick, easy and non-invasive

RELIABLE

  • Clinical studies demonstrate a combined 95% sensitivity in high-risk tumours such as Clinical studies demonstrate a 95% sensitivity in high-grade tumours
  • Has a breakthrough NPV of 97%, allowing clinicians to correctly identify cancer-negative patients with confidence and reliability.

Where does ADXBLADDER fit on the patient pathway?

Data FAQs Publications